Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | SVP, GENERAL COUNSEL | April 09, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date April 09, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2036-04-08 | Direct | 200,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 200,000 · Balance 200,000 F1: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2026 Filed Apr 10, 2026 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001193125-26-151202 · ownership.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 23:54 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001193125-25-310067 · ownership.xml · derivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2024-07-23 F2 · derivative.exercise_date: On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on December 3, 2025 and these shares underlying the option vested. Read SEC document |
| September 26, 2025 Filed Dec 5, 2025 23:54 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001193125-25-310067 · ownership.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-07-23 F1 · derivative.exercise_date: On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-044345 · ownership.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000950170-24-070562 · ownership.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0000950170-24-028613 · ownership.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:27 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-043274 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-23-011249 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:13 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-22-021456 · doc4.xml · derivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2032-03-24 F2 · derivative.exercise_date: 2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. Read SEC document |
| February 09, 2022 Filed Mar 29, 2022 20:13 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001209191-22-021456 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-08 F1 · derivative.exercise_date: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 9, 2022. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:43 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006355 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 13,274 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045702 · doc4.xml · derivative · entry 3 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,100 Underlying: Common Stock · 13,274 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 13,274 | $20.00 | $265,480.00 |
DisclosureSEC source: 0001209191-20-045702 · doc4.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 13,274 | $7.50 | $99,555.00 |
DisclosureSEC source: 0001209191-20-045702 · doc4.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 10, 2020 20:03 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 13,374 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045921 · doc4a.xml · derivative · entry 3 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 13,374 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error. F4 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 05, 2020 Filed Aug 10, 2020 20:03 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 13,374 | $20.00 | $267,480.00 |
DisclosureSEC source: 0001209191-20-045921 · doc4a.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · security: This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 05, 2020 Filed Aug 10, 2020 20:03 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 13,374 | $7.50 | $100,305.00 |
DisclosureSEC source: 0001209191-20-045921 · doc4a.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 201 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · derivative · entry 6 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,374 Underlying: Common Stock · 201 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 201 | $20.05 | $4,030.05 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 4 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 201 | $7.50 | $1,507.50 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 3 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 6,425 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · derivative · entry 5 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,575 Underlying: Common Stock · 6,425 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 6,425 | $20.00 | $128,500.00 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 6,425 | $7.50 | $48,187.50 |
DisclosureSEC source: 0001209191-20-045144 · doc4.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 21:53 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008815 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| June 10, 2019 Filed Jun 10, 2019 22:16 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 14,938 | $7.93 | $118,458.34 |
DisclosureSEC source: 0001209191-19-035958 · doc4.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 10, 2019 Filed Feb 24, 2020 21:56 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 15,025 | $7.90 | $118,697.50 |
DisclosureSEC source: 0001209191-20-012027 · doc4a.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F2 · shares: 87 of these shares were inadvertantly omitted from the Original Form 4, which reported a purchase of 14,938 shares of common stock on June 10, 2019 at a weighted average price of $7.93. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.85 to $7.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 07, 2019 Filed Feb 24, 2020 21:56 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 100 | $7.35 | $735.00 |
DisclosureSEC source: 0001209191-20-012027 · doc4a.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 F1 · shares: This transaction was inadvertantly omitted from the reporting person's original Form 4 filed on June 10, 2019 (the "Original Form 4"). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 22:16 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 2,000 | $7.10 | $14,200.00 |
DisclosureSEC source: 0001209191-19-035958 · doc4.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.04 to $7.16, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:10 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-19-018084 · doc4.xml · derivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-12-27 F2 · derivative.exercise_date: Represents a stock option award granted on December 27, 2017 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 65,000 of these options were vested and exercisable. The remaining 35,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:10 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018084 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| December 27, 2017 Filed Dec 27, 2017 21:48 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-17-067417 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-12-27 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.